PE20061361A1 - USE OF 4-PYRIDYLMETHYL-PHTHALKINE DERIVATIVES AS VEGF-R INHIBITORS - Google Patents
USE OF 4-PYRIDYLMETHYL-PHTHALKINE DERIVATIVES AS VEGF-R INHIBITORSInfo
- Publication number
- PE20061361A1 PE20061361A1 PE2006000398A PE2006000398A PE20061361A1 PE 20061361 A1 PE20061361 A1 PE 20061361A1 PE 2006000398 A PE2006000398 A PE 2006000398A PE 2006000398 A PE2006000398 A PE 2006000398A PE 20061361 A1 PE20061361 A1 PE 20061361A1
- Authority
- PE
- Peru
- Prior art keywords
- phthalkine
- vegf
- inhibitors
- capillary
- patients
- Prior art date
Links
- 229940124674 VEGF-R inhibitor Drugs 0.000 title 1
- -1 4-PYRIDYL Chemical class 0.000 abstract 3
- 108091008605 VEGF receptors Proteins 0.000 abstract 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 abstract 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 abstract 2
- 229950000578 vatalanib Drugs 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract 1
- 229960001756 oxaliplatin Drugs 0.000 abstract 1
- 150000003058 platinum compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE AL USO DE INHIBIDORES DE RECEPTOR DE FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR (VEGF-R) TAL COMO UN DERIVADO DE 4-PIRIDILMETIL-FTALACINA DE FORMULA (I), SIENDO PREFERIDO EL COMPUESTO PTK787 O PTK/ZK O N-(4-CLOROFENIL)-4-(4-PIRIDINILMETIL)-FTALACINAMINA O TAMBIEN DENOMINADO VATALANIB, SOLO O EN COMBINACION CON AL MENOS UN COMPUESTO DE PLATINO TAL COMO OXALIPLATINA Y/O UN ANTIMETABOLITO ANTINEOPLASICO TAL COMO 5-FLUOROURACILO, CAPECITABINA Y OPCIONALMENTE ACIDO FOLINICO, ENTRE OTROS. PARA EL TRATAMIENTO DE PACIENTES CON CANCER GASTROINTESTINAL, GENITOURINARIO, LINFOIDE Y PULMONAR O CANCER DE ORIGEN CRESTA NEURAL, EN ESPECIAL CANCER COLORECTAL, A PACIENTES QUE TIENE ALTO VALORES DE LDHREFERS TO THE USE OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGF-R) INHIBITORS SUCH AS A FORMULA (I) 4-PYRIDYL METHYL-PHTHALKINE DERIVATIVE, THE PTK787 OR PTK / ZK OR N- COMPOUND BEING PREFERRED CHLOROPHENYL) -4- (4-PYRIDINYL METHYL) -PHTHALACINAMINE OR ALSO CALLED VATALANIB, SINGLE OR IN COMBINATION WITH AT LEAST ONE PLATINUM COMPOUND SUCH AS OXALIPLATIN AND / OR AN ANTIMETABOLITE ANTINEUROPLASIUM AND OPOREALYTEAL 5-CAPPETHYLUM IN CAPITALYLUM IN CAPILLARY 5-ATIMETABOLITE, IN CAPILLARY ACIDAL OTHERS. FOR THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL, GENITOURINARY, LYMPHOID AND PULMONARY CANCERS OR CRESTA NEURAL ORIGIN CANCER, ESPECIALLY COLORECTAL CANCER, IN PATIENTS WHO HAVE HIGH LDH VALUES
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67087005P | 2005-04-13 | 2005-04-13 | |
| US68039605P | 2005-05-12 | 2005-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061361A1 true PE20061361A1 (en) | 2007-01-03 |
Family
ID=36649704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000398A PE20061361A1 (en) | 2005-04-13 | 2006-04-17 | USE OF 4-PYRIDYLMETHYL-PHTHALKINE DERIVATIVES AS VEGF-R INHIBITORS |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR053576A1 (en) |
| GT (1) | GT200600147A (en) |
| PE (1) | PE20061361A1 (en) |
| TW (1) | TW200719914A (en) |
| UY (1) | UY29471A1 (en) |
| WO (1) | WO2006113172A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0610925D0 (en) * | 2006-06-02 | 2006-07-12 | Novartis Ag | Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4950519A1 (en) * | 1997-02-13 | 2000-09-01 | Novartis Ag | PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION |
-
2006
- 2006-04-10 GT GT200600147A patent/GT200600147A/en unknown
- 2006-04-10 WO PCT/US2006/013056 patent/WO2006113172A1/en not_active Ceased
- 2006-04-11 AR ARP060101427A patent/AR053576A1/en not_active Application Discontinuation
- 2006-04-11 UY UY29471A patent/UY29471A1/en not_active Application Discontinuation
- 2006-04-12 TW TW095113028A patent/TW200719914A/en unknown
- 2006-04-17 PE PE2006000398A patent/PE20061361A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GT200600147A (en) | 2006-11-24 |
| AR053576A1 (en) | 2007-05-09 |
| UY29471A1 (en) | 2006-11-30 |
| WO2006113172A1 (en) | 2006-10-26 |
| TW200719914A (en) | 2007-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011964A (en) | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof. | |
| PE20090714A1 (en) | IMIDAZOPYRIDAZINES AND PYROLO-PYRIMIDINES SUBSTITUTED AS LIPID KINASE INHIBITORS | |
| CO6180480A2 (en) | PYRIMIDINILPIRAZOLES AS INSECTICIDES AND PARASITICIATED ACTIVE PRINCIPLES | |
| TW200607804A (en) | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals | |
| DE602004022404D1 (en) | 4-ANILINO-CHINAZOLIN DERIVATIVES AS PROLIFERATION-INHIBITABLE AGENTS | |
| EA200870217A1 (en) | 4-Aryl-2-aminopyrimidines or 4-aryl-2-aminoalkylpyrimidines as modulators JAK-2 and containing their pharmaceutical compositions | |
| NO20083923L (en) | Pyrazole quinolones are potent parp inhibitors | |
| CL2008003691A1 (en) | Compounds derived from 4- (phenyl or pyridine) pyrimidine, inhibitors of human neutrophil elastase; preparation procedure; pharmaceutical composition; and use for the treatment and / or prevention of pulmonary arterial hypertension, COPD, pulmonary emphysema, among others. | |
| MX2008005398A (en) | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer. | |
| UA94129C2 (en) | MYTHOSIS INHIBITS | |
| DE602004011199D1 (en) | 5-PHENYLTHIAZOL DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | |
| ATE537830T1 (en) | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTICS | |
| TN2010000053A1 (en) | SUBSTITUTED BI CYCLOLACTAM DERIVATIVES | |
| ATE469158T1 (en) | HETEROALKYL BONDED PYRIMIDINE DERIVATIVES | |
| BRPI0615111B8 (en) | compound, pharmaceutical composition, and use of the compound | |
| CY1115952T1 (en) | PYRIDOLINE PYRASOLINE PRODUCERS AS NADRI OXIDATION INHIBITIONS | |
| CY1111069T1 (en) | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | |
| BRPI0514125A (en) | condensed pyridines as kinase inhibitors | |
| ATE502038T1 (en) | AZYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | |
| ATE406351T1 (en) | CONDENSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | |
| PE20090288A1 (en) | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | |
| NZ594385A (en) | Aminopyrimidines useful as kinase inhibitors | |
| NO20084418L (en) | Azolopyridin-3-one derivatives as inhibitors of endothelial lipase | |
| CY1113556T1 (en) | PYRIDENE PYROZINE PRODUCERS AS NADPH oxidation inhibitors | |
| MY153727A (en) | Pyridazinone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |